Related Experiment Video
Updated: May 3, 2026
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
Novel Animal Models for Multiple Sclerosis: R-Ras GTPases in Myelin Pathophysiology
Gema M Esteban-Ortega1,2, Gonzalo Garcia-Martin1, Beatriz Cubelos1,2
1Centro de Biología Molecular Severo Ochoa (CBM), Universidad Autónoma de Madrid, 28049 Madrid, Spain.
Abstract:
Demyelinating diseases, such as multiple sclerosis, involve oligodendrocyte death, myelin loss, and neuronal death. These processes have been extensively studied, and a causal relationship has been demonstrated between them: destruction of oligodendrocytes results in myelin deficiency, which subsequently leads to neurodegeneration and the consequent loss of sensory, motor, and cognitive functions. Currently, myelinopathies lack fully effective treatments. Available drugs primarily focus on controlling the immune response without directly promoting myelin regeneration or restoring neuronal functionality. Alongside these treatments, pharmaceutical research has increasingly focused on developing therapies that stimulate oligodendroglial lineage differentiation and myelin sheath regeneration. Despite these advances, the lack of suitable preclinical models has been a significant obstacle in evaluating new therapeutic compounds. In this review, we present the main animal models used in the preclinical phase for the study of myelin-related diseases and their role in the development of new therapies. In addition, we highlight the usefulness of R-Ras animal models for assessing the efficacy of compounds that promote oligodendrocyte differentiation.
Insights
Demyelinating diseases like multiple sclerosis cause myelin loss and neurodegeneration. This review explores animal models, including R-Ras models, to test therapies promoting myelin regeneration and oligodendrocyte differentiation.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Demyelinating diseases, such as multiple sclerosis, are characterized by oligodendrocyte death, myelin loss, and subsequent neurodegeneration.
- Current treatments for myelinopathies mainly manage immune responses, lacking direct myelin regeneration or neuronal repair strategies.
- Pharmaceutical research is exploring therapies to stimulate oligodendroglial differentiation and myelin sheath regeneration.
Purpose of the Study:
- To review existing animal models for preclinical studies of myelin-related diseases.
- To evaluate the role of these models in developing novel therapeutic compounds.
- To highlight the utility of R-Ras animal models for assessing pro-oligodendrocyte differentiation therapies.
Main Methods:
- Literature review of preclinical animal models for demyelinating diseases.
- Analysis of the application of these models in therapeutic development.
- Focus on R-Ras models for evaluating oligodendrocyte differentiation agents.
Main Results:
- Various animal models are utilized in the preclinical investigation of myelin-related disorders.
- These models are crucial for assessing the efficacy of potential therapeutic agents.
- R-Ras animal models show promise for evaluating compounds that enhance oligodendrocyte differentiation.
Conclusions:
- Effective preclinical models are essential for advancing treatments for demyelinating diseases.
- R-Ras models offer a valuable platform for testing therapies aimed at myelin repair.
- Further development and utilization of appropriate animal models will accelerate the discovery of effective myelinopathy treatments.
